BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
148 hedge funds and large institutions have $78.3M invested in bluebird bio in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 47 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
40% less call options, than puts
Call options by funds: $758K | Put options by funds: $1.25M
41% less capital invested
Capital invested by funds: $134M → $78.3M (-$55.4M)
Holders
148
Holding in Top 10
–
Calls
$758K
Puts
$1.25M
Top Buyers
| 1 | +$929K | |
| 2 | +$434K | |
| 3 | +$365K | |
| 4 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$350K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$327K |
Top Sellers
| 1 | -$9.87M | |
| 2 | -$3.2M | |
| 3 | -$2.61M | |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$2.19M |
| 5 |
Two Sigma Investments
New York
|
-$1.84M |